These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 17229693

  • 1. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, Ensoli B, Robert-Guroff M.
    J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
    [Abstract] [Full Text] [Related]

  • 2. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [Abstract] [Full Text] [Related]

  • 3. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination.
    Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, Overend P, van Wely C, Thomsen LL, Wahren B, Voss G, Heeney JL.
    J Gen Virol; 2008 Feb; 89(Pt 2):540-5533. PubMed ID: 18198386
    [Abstract] [Full Text] [Related]

  • 4. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J.
    J Virol; 2018 Jan 15; 92(2):. PubMed ID: 29093095
    [Abstract] [Full Text] [Related]

  • 5. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
    Zhao J, Pinczewski J, Gómez-Román VR, Venzon D, Kalyanaraman VS, Markham PD, Aldrich K, Moake M, Montefiori DC, Lou Y, Pavlakis GN, Robert-Guroff M.
    J Virol; 2003 Aug 15; 77(15):8354-65. PubMed ID: 12857905
    [Abstract] [Full Text] [Related]

  • 6. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, Hidajat R, Demberg T, Robert-Guroff M.
    J Virol; 2010 Jul 15; 84(14):7161-73. PubMed ID: 20444898
    [Abstract] [Full Text] [Related]

  • 7. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.
    Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M.
    J Immunol; 2009 Mar 15; 182(6):3718-27. PubMed ID: 19265150
    [Abstract] [Full Text] [Related]

  • 8. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.
    Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M.
    J Virol; 2004 Mar 15; 78(5):2212-21. PubMed ID: 14963117
    [Abstract] [Full Text] [Related]

  • 9. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.
    Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, Kalisz I, Kalyanaraman VS, Pal R, Montefiori D, Keele BF, Robert-Guroff M.
    J Virol; 2012 Apr 15; 86(8):4644-57. PubMed ID: 22345466
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
    De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Venturi V, Davenport MP, Kent SJ.
    J Virol; 2007 Jan 15; 81(1):292-300. PubMed ID: 17050602
    [Abstract] [Full Text] [Related]

  • 11. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
    Patterson LJ, Beal J, Demberg T, Florese RH, Malkevich N, Venzon D, Aldrich K, Richardson E, Kalyanaraman VS, Kalisz I, Lee EM, Montefiori DC, Robey FA, Robert-Guroff M.
    Virology; 2008 May 10; 374(2):322-37. PubMed ID: 18252262
    [Abstract] [Full Text] [Related]

  • 12. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, Moss B.
    Virology; 2002 Mar 15; 294(2):270-81. PubMed ID: 12009868
    [Abstract] [Full Text] [Related]

  • 13. Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.
    Demberg T, Boyer JD, Malkevich N, Patterson LJ, Venzon D, Summers EL, Kalisz I, Kalyanaraman VS, Lee EM, Weiner DB, Robert-Guroff M.
    J Virol; 2008 Nov 15; 82(21):10911-21. PubMed ID: 18753198
    [Abstract] [Full Text] [Related]

  • 14. Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.
    Demberg T, Brocca-Cofano E, Kuate S, Aladi S, Vargas-Inchaustegui DA, Venzon D, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, DiPasquale J, Ruprecht RM, Montefiori DC, Srivastava I, Barnett SW, Robert-Guroff M.
    Virology; 2013 Jun 05; 440(2):210-21. PubMed ID: 23528732
    [Abstract] [Full Text] [Related]

  • 15. Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.
    Martins MA, Tully DC, Pedreño-Lopez N, von Bredow B, Pauthner MG, Shin YC, Yuan M, Lima NS, Bean DJ, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Magnani DM, Ricciardi MJ, Bailey VK, Altman JD, Burton DR, Ejima K, Allison DB, Evans DT, Rakasz EG, Parks CL, Bonaldo MC, Capuano S, Lifson JD, Desrosiers RC, Allen TM, Watkins DI.
    J Virol; 2018 Aug 15; 92(16):. PubMed ID: 29875239
    [Abstract] [Full Text] [Related]

  • 16. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
    McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ.
    J Infect Dis; 2007 Apr 01; 195(7):980-8. PubMed ID: 17330788
    [Abstract] [Full Text] [Related]

  • 17. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV, Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P, Dong M, Choudhary A, Sarkis PT, Bouma P, Zhang Z, Montefiori DC, Vancott TC, Broder CC.
    J Virol; 2005 Mar 01; 79(6):3358-69. PubMed ID: 15731230
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease.
    Fultz PN, Stallworth J, Porter D, Novak M, Anderson MJ, Morrow CD.
    Virology; 2003 Oct 25; 315(2):425-37. PubMed ID: 14585346
    [Abstract] [Full Text] [Related]

  • 19. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B, Le Grand R, Ataman-Onal Y, Terrat C, Guillon C, Durand PY, Hurtrel B, Aubertin AM, Sutter G, Erfle V, Girard M.
    DNA Cell Biol; 2002 Sep 25; 21(9):653-8. PubMed ID: 12396607
    [Abstract] [Full Text] [Related]

  • 20. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.
    Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalyanaraman VS, Pavlakis GN, Robert-Guroff M.
    J Virol; 2003 Aug 25; 77(16):8607-20. PubMed ID: 12885879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.